126TiP SAKK 16/14: Anti-Pd-L1 Antibody Durvalumab (MEDI4736) in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small Cell Lung Cancer (NSCLC): A Multicenter Single-Arm Phase II Trial

Journal of Thoracic Oncology - United States
doi 10.1016/s1556-0864(18)30399-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Combining Antiangiogenic Therapy With Neoadjuvant Chemotherapy Increases Treatment Efficacy in Stage IIIA (N2) Non-Small Cell Lung Cancer Without Increasing Adverse Effects

Oncotarget
Oncology
2016English

P2.01-113 Prognostic Roles of Neoadjuvant and Adjuvant Chemotherapy for Treating Patients With Operable Stage III-N2 Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Durvalumab in Frail and Elderly Patients With Stage Four Non-Small Cell Lung Cancer: Study Protocol of the Randomized Phase II DURATION Trial

Trials
MedicinePharmacology
2020English

Optimal Managements of Stage IIIA (N2) Non-Small Cell Lung Cancer Patients: A Population-Based Survival Analysis

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2017English

P1.16-03 Prognostic Significance of PD-L1 in Stage II/III Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.17-14 Outcomes of Hypofractionated Radiation Therapy (HFRT) With Concurrent Chemotherapy in Patients With Stage III Non Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

A Phase II Trial of Midtreatment PET-CT Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Inoperable/Unresectable Non-Small Cell Lung Cancer (NSCLC)

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

Preoperative Chemotherapy and Radiotherapy Concomitant to Cetuximab in Resectable Stage IIIB NSCLC: A Multicentre Phase 2 Trial (SAKK 16/08)

British Journal of Cancer
Cancer ResearchOncology
2019English

A Nomogram to Predict the Survival of Stage IIIA-N2 Non-Small Cell Lung Cancer After Surgery

Journal of Thoracic and Cardiovascular Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy